Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Thresholds for the Effects of 2-Acetylaminofluorene in Rat Liver

View through CrossRef
To explore for practical thresholds for DNA-reactive carcinogens in rat liver carcinogenicity, we have conducted a series of exposure-response studies using 2 well-studied hepatocarcinogens, 2-acetylaminofluorene (AAF) and diethylnitrosamine (DEN). Findings with AAF, including as yet unpublished experiments, are reviewed here and related to DEN observations. In these studies, we have administered exact intragastric doses during an initiation segment (IS) of 12—16 weeks followed in some experiments by phenobarbital (PB) as a liver tumor promoter for 24 weeks to enhance manifestation of initiation. The cumulative doses (CD) of AAF at the end of ISs ranged from 0.094 to 282.2 mg/kg. Our findings for AAF in the IS can be summarized as follows: (1) the earliest parameter to be affected with administration of low doses was the appearance of DNA adducts (around 4 weeks), followed at higher doses by cell proliferation; (2) formation of DNA adducts was nonlinear, with a no-observed effect level (NOEL) at a CD of 0.094 mg/kg and a plateau at higher doses (94.1 mg/kg); (3) cytotoxicity (necrosis) showed a NOEL at a CD of 28.2 mg/kg; (4) compensatory hepatocellular proliferation showed a NOEL at a CD of 28.2 mg/kg and was supralinear at a high CD (282.2 mg/kg); (5) formation of preneoplastic hepatocellular altered foci (HAF) showed a NOEL at a CD of 28.2 mg/kg, and was supralinear at a high CD (282.2 mg/kg); (6) a NOEL (CD 28.2 mg/kg) was found for tumor development and the exposure—response was supralinear. We interpret these findings to reflect practical thresholds for hepatocellular initiating effects of AAF and exaggerated responses at high-exposures doses, as also found for DEN. Thus, mechanisms of carcinogenesis can differ between low and high doses.
Title: Thresholds for the Effects of 2-Acetylaminofluorene in Rat Liver
Description:
To explore for practical thresholds for DNA-reactive carcinogens in rat liver carcinogenicity, we have conducted a series of exposure-response studies using 2 well-studied hepatocarcinogens, 2-acetylaminofluorene (AAF) and diethylnitrosamine (DEN).
Findings with AAF, including as yet unpublished experiments, are reviewed here and related to DEN observations.
In these studies, we have administered exact intragastric doses during an initiation segment (IS) of 12—16 weeks followed in some experiments by phenobarbital (PB) as a liver tumor promoter for 24 weeks to enhance manifestation of initiation.
The cumulative doses (CD) of AAF at the end of ISs ranged from 0.
094 to 282.
2 mg/kg.
Our findings for AAF in the IS can be summarized as follows: (1) the earliest parameter to be affected with administration of low doses was the appearance of DNA adducts (around 4 weeks), followed at higher doses by cell proliferation; (2) formation of DNA adducts was nonlinear, with a no-observed effect level (NOEL) at a CD of 0.
094 mg/kg and a plateau at higher doses (94.
1 mg/kg); (3) cytotoxicity (necrosis) showed a NOEL at a CD of 28.
2 mg/kg; (4) compensatory hepatocellular proliferation showed a NOEL at a CD of 28.
2 mg/kg and was supralinear at a high CD (282.
2 mg/kg); (5) formation of preneoplastic hepatocellular altered foci (HAF) showed a NOEL at a CD of 28.
2 mg/kg, and was supralinear at a high CD (282.
2 mg/kg); (6) a NOEL (CD 28.
2 mg/kg) was found for tumor development and the exposure—response was supralinear.
We interpret these findings to reflect practical thresholds for hepatocellular initiating effects of AAF and exaggerated responses at high-exposures doses, as also found for DEN.
Thus, mechanisms of carcinogenesis can differ between low and high doses.

Related Results

PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1.Effect of chronic haloperidol treatment on D‐2 receptors labelled by (3H)‐spiperone in homogenates of rat corpus striatum. A. L. Gundlach, D. J. de Vries and P. M. Beart2.The eff...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
14th Annual Meeting, December 1980, Canberra1. Effect of dexamethasone on pineal β‐adrenoceptors. C. A. Maxwell, A. Foldes, N. T. Hinks and R. M. Hoskinson2. A clinicopathological ...
EVALUATION AND COMPARISON OF LIVER MARKERS IN ACUTE LIVER FAILURE VS CHRONIC LIVER FAILURE IN DISTRICT FAISALABAD: A CROSS-SECTIONAL STUDY
EVALUATION AND COMPARISON OF LIVER MARKERS IN ACUTE LIVER FAILURE VS CHRONIC LIVER FAILURE IN DISTRICT FAISALABAD: A CROSS-SECTIONAL STUDY
Background: Liver failure is a life-threatening clinical condition resulting from the inability of the liver to maintain its metabolic, synthetic, and detoxification functions. Acu...
[RETRACTED] Keanu Reeves CBD Gummies v1
[RETRACTED] Keanu Reeves CBD Gummies v1
[RETRACTED]Keanu Reeves CBD Gummies ==❱❱ Huge Discounts:[HURRY UP ] Absolute Keanu Reeves CBD Gummies (Available)Order Online Only!! ❰❰= https://www.facebook.com/Keanu-Reeves-CBD-G...
Expression and characterization of rat kallikrein-binding protein in Escherichia coli
Expression and characterization of rat kallikrein-binding protein in Escherichia coli
Rat kallikrein-binding protein is a novel serine-proteinase inhibitor that forms a covalent complex with tissue kallikrein. We have purified rat kallikrein-binding protein and clon...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
10th Annual Meeting, 25‐26 November 1976, Adelaide 1. Histamine metabolism in aortae of two histamine sensitive species. A. Foldes, M. J. Stacey and I. S. de la Lande 2. Localizat...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1. The development of the prejunctional receptor hypothesis. M.W. McCulloch, M.J. Rand and D. F. Story2. Adrenoceptor‐ and cholinoceptor‐mediated modulation of transmitter release ...

Back to Top